Jason Najum talks to Srinivas Rao, CEO of Atai Life Sciences, a biotech company focused on mental health and psychedelic compounds.

Avesta Ketamine and Wellness (Avesta), the leading provider of monitored ketamine care in the Washington, D.C., Maryland and ...

Compass Pathways gains Stifel's Buy rating as its COMP360 psilocybin treatment advances in Phase 3 trials. Key depression study data expected in 2025-2026.

Stock Advisor provides investors with an easy-to-follow blueprint for success, including guidance on building a portfolio, regular updates from analysts, and two new stock picks each month. The Stock ...

Stifel has initiated Compass Pathways (NASDAQ:CMPS) with a buy rating saying that stakeholders are starting to agree there is ...